Troy Edward Wilson Purchases 100,000 Shares of Kura Oncology (NASDAQ:KURA) Stock

Kura Oncology, Inc. (NASDAQ:KURA) CEO Troy Edward Wilson purchased 100,000 shares of the business’s stock in a transaction on Monday, August 17th. The stock was acquired at an average price of $11.12 per share, with a total value of $1,112,000.00. Following the purchase, the chief executive officer directly owned 379,194 shares in the company, valued at $4,216,637.28. This represents a 35.82% increase in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Kura Oncology Price Performance

NASDAQ:KURA traded up $0.42 on Monday, reaching $11.28. 2,042,243 shares of the company’s stock traded hands, compared to its average volume of 1,575,846. The stock has a 50-day simple moving average of $10.22 and a 200-day simple moving average of $9.34. Kura Oncology, Inc. has a 12 month low of $6.95 and a 12 month high of $12.49. The firm has a market cap of $1.00 billion, a PE ratio of -3.35 and a beta of 0.38. The company has a quick ratio of 4.71, a current ratio of 4.73 and a debt-to-equity ratio of 0.12.

Kura Oncology (NASDAQ:KURA) last released its quarterly earnings data on Wednesday, August 12th. The company reported ($0.77) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.88) by $0.11. The firm had revenue of $20.87 million during the quarter, compared to analyst estimates of $20.16 million. Kura Oncology had a negative return on equity of 207.18% and a negative net margin of 384.30%. Equities research analysts forecast that Kura Oncology, Inc. will post -3.3 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Hennion & Walsh Asset Management Inc. lifted its holdings in Kura Oncology by 69.7% during the second quarter. Hennion & Walsh Asset Management Inc. now owns 568,845 shares of the company’s stock worth $6,240,000 after buying an additional 233,633 shares during the period. Dimensional Fund Advisors LP increased its holdings in shares of Kura Oncology by 32.3% in the 1st quarter. Dimensional Fund Advisors LP now owns 1,425,945 shares of the company’s stock valued at $11,591,000 after acquiring an additional 348,127 shares during the period. UBS Group AG raised its position in shares of Kura Oncology by 118.3% in the 4th quarter. UBS Group AG now owns 1,060,025 shares of the company’s stock worth $11,014,000 after acquiring an additional 574,455 shares in the last quarter. Nan Fung Trinity HK Ltd. raised its position in shares of Kura Oncology by 317.9% in the 4th quarter. Nan Fung Trinity HK Ltd. now owns 964,880 shares of the company’s stock worth $10,025,000 after acquiring an additional 734,000 shares in the last quarter. Finally, Janney Montgomery Scott LLC lifted its stake in shares of Kura Oncology by 285.6% during the 1st quarter. Janney Montgomery Scott LLC now owns 158,850 shares of the company’s stock worth $1,291,000 after purchasing an additional 117,650 shares during the last quarter.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Kura Oncology in a research report on Friday, July 17th. Wedbush upped their target price on shares of Kura Oncology from $36.00 to $38.00 and gave the stock an “outperform” rating in a research report on Thursday. Jefferies Financial Group set a $24.00 target price on shares of Kura Oncology in a research note on Thursday, May 28th. CLSA set a $24.00 price target on shares of Kura Oncology in a report on Thursday, June 4th. Finally, Wall Street Zen upgraded shares of Kura Oncology from a “strong sell” rating to a “hold” rating in a research note on Saturday, May 16th. Ten equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $25.62.

About Kura Oncology

Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura’s research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.

The company’s lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.